Aktie A2QESU EOM PHARMACEUTICALS HOLDINGS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen EOM Pharmaceuticals Holdings, Inc.

Aktien

A2QESU

US4525364026

IMUC

Markt geschlossen - OTC Markets
Andere Börsenplätze
 20:19:09 26.04.2024 		% 5 Tage % 1. Jan.
0,1979 USD 0,00 % Intraday Chart für EOM Pharmaceuticals Holdings, Inc. 0,00 % -14,70 %
2023 EOM Pharmaceutical Holdings gibt Topline-Ergebnisse der klinischen Covid-19-Studie mit Eom613 in Brasilien bekannt CI
2023 EOM Pharmaceuticals Holdings, Inc. hat seinen Börsengang in Höhe von $15 Millionen zurückgezogen. CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil
EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil
EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.
EOM Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
ImmunoCellular Therapeutics Ltd. has Changed its Name to EOM Pharmaceuticals Holdings, Inc
EOM Pharmaceuticals Holdings, Inc. announced that it has received $0.75 million in funding
EOM Pharmaceuticals Holdings, Inc. announced a financing transaction
EOM Pharmaceuticals Holdings, Inc. has filed an IPO in the amount of $25 million.
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.
ImmunoCellular Therapeutics : Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
ImmunoCellular Therapeutics, Ltd.(AMEX:IMUC) dropped from S&P TMI Index
ImmunoCellular Therapeutics, Ltd. Announces Executive Changes, Effective October 15, 2018
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018
ImmunoCellular Therapeutics Is Considering Strategic Alternatives
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018
ImmunoCellular Therapeutics, Ltd. Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QESU Aktie
  4. Nachrichten EOM Pharmaceuticals Holdings, Inc.
  5. Andere Sprachen